Koppel Adam
SEC Form 4 insider trading activity
Koppel Adam has filed 1 SEC Form 4 filing (3 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Apr 20, 2026.
On the most recent filing, Koppel Adam is listed as Director, 10% Owner at Kailera Therapeutics, Inc. Inside the rolling window, Koppel Adam reported 1 open-market purchase totaling $25.0M in KLRA and no open-market sales.
Companies traded
Other insiders at KLRA
Insider Buying
$25.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Koppel Adam made?
Koppel Adam has filed 1 SEC Form 4 filing (3 transaction rows) across 1 company since 2026.
Which companies does Koppel Adam trade?
Koppel Adam has filed SEC Form 4 disclosures for 1 company, including KLRA.
When was Koppel Adam's most recent SEC Form 4 filing?
Koppel Adam's most recent SEC Form 4 filing on Tracefour is dated Apr 20, 2026.
What is Koppel Adam's total buy and sell value in the current window?
Inside the rolling retention window, Koppel Adam bought $25.0M and sold $0 based on SEC Form 4 filings.
What was Koppel Adam's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 1,562,500 KLRA shares on 2026-04-20, worth $25.0M, per SEC Form 4 filings.